Evidence map›Paper›PMID 36250091›Full record

ArticleFrontiers in medicine2022

Molecular characterization of a new SARS-CoV-2 recombinant cluster XAG identified in Brazil.

Thaís de Souza Silva, Richard Steiner Salvato, Tatiana Schäffer Gregianini, Ighor Arantes Gomes, Elisa Cavalcante Pereira, Eneida de Oliveira, André Luiz de Menezes, Regina Bones Barcellos, Fernanda Marques Godinho, Irina Riediger and 13 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Enhancing the epidemiological surveillance of SARS-CoV-2 using Sanger sequencing to identify circulating variants and recombinants.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Thaís de Souza SilvaInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Richard Steiner SalvatoLaboratório Central de Saúde Pública do Estado do Rio Grande do Sul, Porto Alegre, Brazil.
Tatiana Schäffer GregianiniLaboratório Central de Saúde Pública do Estado do Rio Grande do Sul, Porto Alegre, Brazil.
Ighor Arantes GomesInstituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Elisa Cavalcante PereiraInstituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Eneida de OliveiraLaboratório Municipal de Referência, Setor de Biologia Molecular, Belo Horizonte, Brazil.
André Luiz de MenezesLaboratório Municipal de Referência, Setor de Biologia Molecular, Belo Horizonte, Brazil.
Regina Bones BarcellosCentro de Desenvolvimento Científico e Tecnológico, Porto Alegre, Brazil.
Fernanda Marques GodinhoCentro de Desenvolvimento Científico e Tecnológico, Porto Alegre, Brazil.
Irina RiedigerLaboratório Central de Saúde Pública do Estado do Paraná, Curitiba, Brazil.
Maria do Carmo DeburLaboratório Central de Saúde Pública do Estado do Paraná, Curitiba, Brazil.
Cristina Mendes de OliveiraDasa, Barueri, Brazil.
Rodrigo Ribeiro-RodriguesLaboratório Central de Saúde Pública do Estado do Espírito Santo, Vitória, Brazil.
Fabio MiyajimaFiocruz Ceará, Fundação Oswaldo Cruz, Eusébio, Brazil.
Fernando Stehling DiasFiocruz Ceará, Fundação Oswaldo Cruz, Eusébio, Brazil.
Adriano AbbudInstituto Adolfo Lutz, São Paulo, Brazil.
Rubens do Monte-NetoInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Carlos Eduardo Calzavara-SilvaInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Marilda Mendonça SiqueiraInstituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Gabriel Luz WallauInstituto Aggeu Magalhães, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Paola Cristina ResendeInstituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Gabriel da Rocha FernandesInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Pedro AlvesInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombination events have been described in the Coronaviridae family. Since the beginning of the SARS-CoV-2 pandemic, a variable degree of selection pressure has acted upon the virus, generating new strains with increased fitness in terms of viral transmission and antibody scape. Most of the SC2 variants of concern (VOC) detected so far carry a combination of key amino acid changes and indels. Recombination may also reshuffle existing genetic profiles of distinct strains, potentially giving origin to recombinant strains with altered phenotypes. However, co-infection and recombination events are challenging to detect and require in-depth curation of assembled genomes and sequencing reds. Here, we present the molecular characterization of a new SARS-CoV-2 recombinant between BA.1.1 and BA.2.23 Omicron lineages identified in Brazil. We characterized four mutations that had not been previously described in any of the recombinants already identified worldwide and described the likely breaking points. Moreover, through phylogenetic analysis, we showed that the newly named XAG lineage groups in a highly supported monophyletic clade confirmed its common evolutionary history from parental Omicron lineages and other recombinants already described. These observations were only possible thanks to the joint effort of bioinformatics tools auxiliary in genomic surveillance and the manual curation of experienced personnel, demonstrating the importance of genetic, and bioinformatic knowledge in genomics.

Indexed as

genomic surveillanceomicronrecombinantSARS-CoV-2variantsXAG

Identifiers

PMID36250091
PMCPMC9554242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.